|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ИНХС РАН |
||
A Translational Systems Pharmacology Model for A$\upbeta$ Kinetics in Mouse, Monkey, and Humanстатья
- Авторы: Karelina T., Demin O., Nicholas T., Lu Y., Duvvuri S., Barton H.A.
- Журнал: CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY
- Год издания: 2017
- DOI: 10.1002/psp4.12211
- Аннотация: A mechanistic model of amyloid beta production, degradation, and distribution was constructed for mouse, monkey, and human, calibrated and externally verified across multiple datasets. Simulations of single-dose avagacestat treatment demonstrate that the Aβ42 brain inhibition may exceed that in cerebrospinal fluid (CSF). The dose that achieves 50% CSF Aβ40 inhibition for humans (both healthy and with Alzheimer's disease (AD)) is about 1 mpk, one order of magnitude lower than for mouse (10 mpk), mainly because of differences in pharmacokinetics. The predicted maximal percent of brain Aβ42 inhibition after single-dose avagacestat is higher for AD subjects (about 60%) than for healthy individuals (about 45%). The probability of achieving a normal physiological level for Aβ42 in brain (1 nM) during multiple avagacestat dosing can be increased by using a dosing regimen that achieves higher exposure. The proposed model allows prediction of brain pharmacodynamics for different species given differing dosing regimens.
- Добавил в систему: Демин Олег Владимирович